5-MeO-MiPT: Difference between revisions

(3 intermediate revisions by 3 users not shown)

Line 17:

==Pharmacology==

5-MeO-MiPT's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]]<ref name="pmid17223101">{{cite journal|title=The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain|pmid=17223101|volume=559|issue=2–3|year=2007|pages=132-137|first1=F.|last1=Nagai|first2=R.|last2=Nonaka|first3=K.|last3=Satoh|first4=H.|last4=Kamimura|journal=European Journal of Pharmacology|issn=0014-2999|eissn=1879-0712|oclc=01568459|doi=10.1016/j.ejphar.2006.11.075}}</ref><ref name="Repke1985" /> and additional mechanisms of action such as the inhibition of [[MAOI|MAO]] (i.e. digestive enzymes in the stomach) have also been speculated upon, though this has yet to be demonstrated scientifically. While 5-MeO-MiPT binds most strongly to 5-HT1A receptors, ~~it also shows fairly strong binding affinity to the SERT and NET, thereby acting~~ as a moderately potent serotonin-norepinephrine reuptake inhibitor.<ref>{{cite journal | vauthors=((Ray, T. S.)) | journal=PLoS ONE | title=Correction: Psychedelics and the Human Receptorome | volume=5 | issue=3 | date=4 March 2010 | url=https://dx.plos.org/10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4 | issn=1932-6203 | doi=10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4}}</ref> These mechanisms may help explain why there are many anecdotal reports of anti-depressant and anxiolytic effects from modest doses of this compound. For example, SNRIs such as venlafaxine are commonly prescribed to treat depression, and the 5-HT1A agonist buspirone is prescribed primarily for treatment of anxiety.

5-MeO-MiPT's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]]<ref name="pmid17223101">{{cite journal|title=The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain|pmid=17223101|volume=559|issue=2–3|year=2007|pages=132-137|first1=F.|last1=Nagai|first2=R.|last2=Nonaka|first3=K.|last3=Satoh|first4=H.|last4=Kamimura|journal=European Journal of Pharmacology|issn=0014-2999|eissn=1879-0712|oclc=01568459|doi=10.1016/j.ejphar.2006.11.075}}</ref><ref name="Repke1985" /> and additional mechanisms of action such as the inhibition of [[MAOI|MAO]] (i.e. digestive enzymes in the stomach) have also been speculated upon, though this has yet to be demonstrated scientifically. While 5-MeO-MiPT binds most strongly to 5-HT1A receptors, It might act as a moderately potent serotonin-norepinephrine reuptake inhibitor<ref>{{cite journal | vauthors=((Ray, T. S.)) | journal=PLoS ONE | title=Correction: Psychedelics and the Human Receptorome | volume=5 | issue=3 | date=4 March 2010 | url=https://dx.plos.org/10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4 | issn=1932-6203 | doi=10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4}}</ref> but other studies have not found significant action at the monoamine transporters[https://www.sciencedirect.com/science/article/abs/pii/S0924977X16300426]. These mechanisms may help explain why there are many anecdotal reports of anti-depressant and anxiolytic effects from modest doses of this compound. For example, SNRIs such as venlafaxine are commonly prescribed to treat depression, and the 5-HT1A agonist buspirone is prescribed primarily for treatment of anxiety.

==Subjective effects==

Line 23:

{{effects/base

|{{effects/physical|

Line 76:

Line 77:

*'''[[Effect::Increased music appreciation]]'''

*'''[[Effect::Emotion enhancement]]'''

*'''[[Effect::Increased libido]]'''

*'''[[Effect::Increased libido]]''' - increased libido and significantly enhanced orgasms are reported

*'''[[Effect::Memory suppression]]'''

*'''[[Effect::Novelty enhancement]]'''

Line 165:

Line 166:

*'''Romania''': 5-MeO-MiPT and other derivatives are illegal in Romania, as of January 2011.{{citation needed}}

*'''Switzerland''': 5-MeO-MiPT is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>

*'''Turkey:''' 5-MeO-MiPT is classed as a drug and is illegal to possess, produce, supply, or import.<ref>Bakanlar Kurulu Kararı Karar Sayısı : 2013/4827 | https://free-ankara.org/wp-content/uploads/2017/09/BKK_2013_4827_28688.pdf</ref>

*'''United Kingdom''': 5-MeO-MiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-MiPT, which is a Class A drug as a result of the tryptamine catch-all clause.<ref>{{cite web|title=Schedule 2: Part I: Class A Drugs|url=http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I|work="Misuse of Drugs Act 1971"|access-date=August 20, 2020|publisher=UK Government}}</ref>

*'''United States''': 5-MeO-MiPT is unscheduled in the United States. It may be considered an analogue of [[5-MeO-DiPT]], a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.<ref>https://www.law.cornell.edu/uscode/text/21/813</ref>

@@ Line 17: / Line 17: @@
 ==Pharmacology==
 {{Further|Serotonergic psychedelic}}
--MeO-MiPT's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]]<ref name="pmid17223101">{{cite journal|title=The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain|pmid=17223101|volume=559|issue=2–3|year=2007|pages=132-137|first1=F.|last1=Nagai|first2=R.|last2=Nonaka|first3=K.|last3=Satoh|first4=H.|last4=Kamimura|journal=European Journal of Pharmacology|issn=0014-2999|eissn=1879-0712|oclc=01568459|doi=10.1016/j.ejphar.2006.11.075}}</ref><ref name="Repke1985" /> and additional mechanisms of action such as the inhibition of [[MAOI|MAO]] (i.e. digestive enzymes in the stomach) have also been speculated upon, though this has yet to be demonstrated scientifically. While 5-MeO-MiPT binds most strongly to 5-HT1A receptors, it also shows fairly strong binding affinity to the SERT and NET, thereby acting as a moderately potent serotonin-norepinephrine reuptake inhibitor.<ref>{{cite journal | vauthors=((Ray, T. S.)) | journal=PLoS ONE | title=Correction: Psychedelics and the Human Receptorome | volume=5 | issue=3 | date=4 March 2010 | url=https://dx.plos.org/10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4 | issn=1932-6203 | doi=10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4}}</ref> These mechanisms may help explain why there are many anecdotal reports of anti-depressant and anxiolytic effects from modest doses of this compound. For example, SNRIs such as venlafaxine are commonly prescribed to treat depression, and the 5-HT1A agonist buspirone is prescribed primarily for treatment of anxiety.
+-MeO-MiPT's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]]<ref name="pmid17223101">{{cite journal|title=The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain|pmid=17223101|volume=559|issue=2–3|year=2007|pages=132-137|first1=F.|last1=Nagai|first2=R.|last2=Nonaka|first3=K.|last3=Satoh|first4=H.|last4=Kamimura|journal=European Journal of Pharmacology|issn=0014-2999|eissn=1879-0712|oclc=01568459|doi=10.1016/j.ejphar.2006.11.075}}</ref><ref name="Repke1985" /> and additional mechanisms of action such as the inhibition of [[MAOI|MAO]] (i.e. digestive enzymes in the stomach) have also been speculated upon, though this has yet to be demonstrated scientifically. While 5-MeO-MiPT binds most strongly to 5-HT1A receptors, It might act as a moderately potent serotonin-norepinephrine reuptake inhibitor<ref>{{cite journal | vauthors=((Ray, T. S.)) | journal=PLoS ONE | title=Correction: Psychedelics and the Human Receptorome | volume=5 | issue=3 | date=4 March 2010 | url=https://dx.plos.org/10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4 | issn=1932-6203 | doi=10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4}}</ref> but other studies have not found significant action at the monoamine transporters[https://www.sciencedirect.com/science/article/abs/pii/S0924977X16300426]. These mechanisms may help explain why there are many anecdotal reports of anti-depressant and anxiolytic effects from modest doses of this compound. For example, SNRIs such as venlafaxine are commonly prescribed to treat depression, and the 5-HT1A agonist buspirone is prescribed primarily for treatment of anxiety.
 ==Subjective effects==
@@ Line 23: / Line 23: @@
 {{Preamble/SubjectiveEffects}}
 {{effects/base
 |{{effects/physical|
@@ Line 76: / Line 77: @@
 *'''[[Effect::Increased music appreciation]]'''
 *'''[[Effect::Emotion enhancement]]'''
-*'''[[Effect::Increased libido]]'''
+*'''[[Effect::Increased libido]]''' - increased libido and significantly enhanced orgasms are reported
 *'''[[Effect::Memory suppression]]'''
 *'''[[Effect::Novelty enhancement]]'''
@@ Line 165: / Line 166: @@
 *'''Romania''': 5-MeO-MiPT and other derivatives are illegal in Romania, as of January 2011.{{citation needed}}
 *'''Switzerland''': 5-MeO-MiPT is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
+*'''Turkey:''' 5-MeO-MiPT is classed as a drug and is illegal to possess, produce, supply, or import.<ref>Bakanlar Kurulu Kararı Karar Sayısı : 2013/4827 | https://free-ankara.org/wp-content/uploads/2017/09/BKK_2013_4827_28688.pdf</ref>
 *'''United Kingdom''': 5-MeO-MiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-MiPT, which is a Class A drug as a result of the tryptamine catch-all clause.<ref>{{cite web|title=Schedule 2: Part I: Class A Drugs|url=http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I|work="Misuse of Drugs Act 1971"|access-date=August 20, 2020|publisher=UK Government}}</ref>
 *'''United States''': 5-MeO-MiPT is unscheduled in the United States. It may be considered an analogue of [[5-MeO-DiPT]], a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.<ref>https://www.law.cornell.edu/uscode/text/21/813</ref>